Hern H Gene, Lara Vanessa, Cantwell-Frank Dre, Abusaa Sarah, Rosen Allison D, Herring Andrew A
EMS Bridge, Contra Costa Operations, Global Medical Response, Alameda Health System - Highland Hospital, Emergency Medicine, Oakland, California.
EMS Bridge, Oakland, California.
Prehosp Emerg Care. 2025;29(4):450-457. doi: 10.1080/10903127.2024.2445075. Epub 2025 Jan 31.
Opioids kill tens of thousands of patients each year. While only a fraction of people with opioid use disorder (OUD) have accessed treatment in the last year, 30% of people who died from an overdose had an Emergency Medical Services (EMS) encounter within a year of their death. Prehospital buprenorphine represents an important emerging OUD treatment, yet limited data describe barriers to this treatment. Our objectives were to quantify the number of patients encountered by EMS who were eligible for prehospital buprenorphine, and to examine characteristics of patients who did or did not receive treatment.
In this retrospective observational study, we analyzed EMS patient records from Contra Costa County, CA, where paramedics were trained to identify patients experiencing opioid withdrawal and administer buprenorphine. Patient records were selected for review based on "buprenorphine patient triggers," which were keywords within the charts that identified patients with potential overdose or symptoms that could indicate withdrawal or naloxone administration. We describe proportion of eligible patients and the characteristics of those who did and did not receive prehospital buprenorphine.
We reviewed 1,159 records from September 2020 to July 2022. Of included patients, 984 (85%) were not eligible for buprenorphine. Nearly half (482, 49%,) of patients ineligible for buprenorphine fell into 2 primary categories: 331 (33%) had altered mental status (326 of 331 received naloxone), and 151 (15%) had no active withdrawal symptoms documented. Additional exclusions included other intoxicants, severe medical illness, or the patient denied having an OUD. Of those eligible for buprenorphine, 67 (38%) received buprenorphine. Of the 108 patients who did not receive buprenorphine, 69 (64%) had protocol deviation, 24 (22%) declined treatment, and 15 (14%) were in a non-enabled zone. Of all buprenorphine administrations, 19 (28%) were post-opioid overdose and 48 (72%) were for abstinence withdrawal.
One-in-three EMS patients with suspected opioid use disorder were ineligible for treatment with buprenorphine due to altered mental status. The second largest group consisted of patients who were eligible but not offered buprenorphine, highlighting potential gaps in paramedic training, logistical challenges in field administrations, and other factors that warrant further exploration.
阿片类药物每年导致数万人死亡。虽然去年只有一小部分患有阿片类药物使用障碍(OUD)的人接受了治疗,但30%死于过量用药的人在死亡前一年内曾与紧急医疗服务(EMS)接触过。院前使用丁丙诺啡是一种重要的新兴OUD治疗方法,但关于这种治疗的障碍的数据有限。我们的目标是量化EMS接触到的符合院前使用丁丙诺啡条件的患者数量,并检查接受或未接受治疗的患者的特征。
在这项回顾性观察研究中,我们分析了加利福尼亚州康特拉科斯塔县的EMS患者记录,在那里护理人员接受了识别阿片类药物戒断患者并给予丁丙诺啡的培训。根据“丁丙诺啡患者触发因素”选择患者记录进行审查,这些触发因素是图表中的关键词,用于识别有潜在过量用药或可能表明戒断或使用纳洛酮症状的患者。我们描述了符合条件的患者比例以及接受和未接受院前丁丙诺啡治疗的患者的特征。
我们审查了2020年9月至2022年7月的1159份记录。在纳入的患者中,984人(85%)不符合使用丁丙诺啡的条件。不符合使用丁丙诺啡条件的患者中近一半(482人,49%)属于两个主要类别:331人(33%)精神状态改变(331人中的326人接受了纳洛酮),151人(15%)没有记录到活跃的戒断症状。其他排除因素包括其他中毒、严重疾病或患者否认患有OUD。在符合使用丁丙诺啡条件的患者中,67人(38%)接受了丁丙诺啡治疗。在未接受丁丙诺啡治疗的108名患者中,69人(64%)存在方案偏差,24人(22%)拒绝治疗,15人(14%)处于未启用区域。在所有丁丙诺啡给药中,19次(28%)是在阿片类药物过量用药后,48次(72%)是用于戒断。
三分之一疑似患有阿片类药物使用障碍的EMS患者因精神状态改变而不符合使用丁丙诺啡治疗的条件。第二大群体是符合条件但未接受丁丙诺啡治疗的患者,这突出了护理人员培训方面的潜在差距、现场给药的后勤挑战以及其他需要进一步探索的因素。